In a 25-year-old woman, admitted with a haemorrhagic syndrome following biliary surgery, an inhibitor of factor VIII was detected. As bleeding was major, she was re-operated on under perioperative administration of the anti-inhibitory coagulant complex Autoplex-T, associated with polyvalent i.v. immunoglobulins. The other therapeutic agents are also considered and their indications discussed, after a review of the circumstances of the diagnosis of this disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0750-7658(94)80200-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Danaparoid-Consensus Recommendations on Its Clinical Use.
Pharmaceuticals (Basel)
November 2024
Independent Researcher, 5345 MT Oss, The Netherlands.
(1) Background: Danaparoid sodium is a heparinoid antithrombotic that has been used for over 40 years for prophylaxis of DVT in non-HIT patients and for the treatment of heparin-induced thrombocytopenia (HIT) with and without thrombosis. This update summarises current information on its pharmacology and reviews danaparoid dose management in a broad spectrum of clinical situations, including off-label indications. (2) Methods: Evidence from published clinical studies, case reports, compassionate use of danaparoid, and spontaneously reported serious adverse events is summarised and analysed by an interdisciplinary expert group to develop a consensus on dosing regimens of danaparoid for complex clinical situations, including vulnerable patient populations.
View Article and Find Full Text PDFChildhood onset C3 glomerulopathy: recurrence after kidney transplantation-a case series.
Front Pediatr
October 2024
School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Background: C3 Glomerulopathy (C3G) is a complement-mediated disease, with predominant C3 deposits, where pathogenic genetic variants in complement system components and circulating autoantibodies result in loss of control of the alternative pathway, have been described. A high incidence of disease recurrence including graft failure has been reported after kidney transplantation (KTx). Currently treatment modalities for preventing and treating post KTx C3G recurrence (plasma exchange, rituximab and eculizumab) in adults have yielded inconsistent results.
View Article and Find Full Text PDFChemokine CXCL13 facilitates anti-FVIII inhibitory antibody development in hemophilia A patients and murine models.
Int Immunopharmacol
December 2024
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China; Medical Technology and Engineering College of Fujian Medical University, Fuzhou, Fujian, China; Key Laboratory of Clinical Laboratory Technology for Precision Medicine (Fujian Medical University), Fujian Province University, Fuzhou, China. Electronic address:
Article Synopsis
- The study investigates the formation of anti-factor VIII (FVIII) inhibitors in hemophilia A patients and the role of the chemokine CXCL13 in this process.
- It was found that CXCL13 levels were significantly elevated in hemophilia A patients with inhibitors compared to those without, suggesting a link between CXCL13 and inhibitor development.
- The research indicates that targeting CXCL13 could be a promising therapeutic strategy for managing FVIII inhibitors in hemophilia A patients.
Evaluating chemical venous thromboembolism prophylaxis in trauma patients at a single Australian center.
J Trauma Inj
September 2024
Intensive Care Unit, Canberra Hospital, Garran, ACT, Australia.
Purpose: Trauma patients are at an elevated risk of developing venous thromboembolism (VTE), with the subsequent mortality in patients requiring intensive care unit admission ranging from 25% to 38%. There remains significant variability in clinical practice related to VTE prophylaxis in trauma patients due to the frequent presence of contraindications impacting the timing and consistency of application. This study aimed to assess the effectiveness of the current practice of chemical VTE prophylaxis in trauma patients at a single Australian center.
View Article and Find Full Text PDFInduction of factor VIII tolerance by hemophilia gene transfer to eradicate factor VIII inhibitors.
Blood Adv
January 2025
Cancer and Blood Disorders Institute, Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA.
Patients with hemophilia A can develop antifactor antibodies to factor VIII. The incidence is ∼30%, and such patients suffer worse morbidity and mortality. The only proven method to eradicate these inhibitors is via immune tolerance induction therapy, which consists of infusing factor VIII concentrates at regular intervals.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!